PURPOSE: Prior to October 2008 there were long waiting lists for spirometry in most pulmonary function laboratories within BC. In October 2008 a walk-in spirometry laboratory was opened at The Lung Centre in order to improve access to spirometry. We review here the demographics of patients being referred to the service, the number of patients referred with suspected COPD and the percentage of these patients who have abnormal versus normal results. The number of referrals, per month, over an 18-month period was also recorded.
METHODS: Referrals from October 2008 to March 2010 were analyzed. Data collected included: reason for referral, age, gender, smoking history, current treatment and suspected diagnosis. The spirometric data was analyzed and classified as normal or obstructive (according to CTS guidelines). The severity of obstruction was recorded (using CTS guidelines for classification of severity) and bronchodilator response (where applicable, using ATS guidelines for classification of a positive response).
RESULTS: From October 2008 to March 2010, 2155 patients attended the laboratory for spirometry. In October 2008 the laboratory received 1 patient referral. In March 2010 the laboratory received 240 patient referrals, with an average of 120 referrals per month over the 18-month period.Further analysis of demographics, reason for referral and classification of spirometric data will be presented at the meeting.
CONCLUSION: The volume of referrals increased between October 2008 and March 2010. A significant portion of patients were referred with a suspected diagnosis of COPD and of all patients tested, a substantial number yielded abnormal results.
CLINICAL IMPLICATIONS: A continued effort to improve access to spirometry and promote these services is essential. As availability increases, emphasis should be placed on educating health care professionals in the importance of spirometry for early detection, and monitoring, of pulmonary disease.
DISCLOSURE: Kelly Sallaway, Grant monies (from sources other than industry) Current funding is also provided by the Lower Mainland Innovation Fund.; Grant monies (from industry related sources) Initial funding for this project was provided by Pfizer, and Boehringer Ingelheim.; No Product/Research Disclosure Information